Where the Bodies Lie. Ben-Joseph, O. Nat Biotechnol. 2016 Sep 8; 34(9):909-11. doi: 10.1038/nbt.3660.
Introduction: As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the exit—the sole event where company investors receive a return on their investment, either through an initial public offering (IPO) or a company sale. Unfortunately, the biotech industry’s track record on exits is disappointing. According to the National Venture Capital Association (Washington, DC), between 2005 and 2014, only one in five US biotech and medical device companies achieved liquidity after six years. And from my perspective over the past 20 years, that low success rate does not appear to be improving.
In the following article I share my perspective on common pitfalls for life sciences entrepreneurs. Going forward, I hope that these insights will help life sciences management teams increase their chances of success.
Outcome Capital and Partners HealthCare Innovation Collaborate through the Innovation Fellows Program to Provide Experience in the Business of Science June 4, 2019, Boston, MA Outcome Capital, LLC announced today that it has expanded the Outcome Capital Internship Program to include Partners HealthCare Innovation. The program will provide research fellows at Massachusetts General Hospital, Brigham […]Read More
Outcome Capital Advises Whisker Labs in the Sale of its Energy Management Business to Resideo Technologies May 29, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has sold its Energy Management […]Read More